China SXT Pharmaceuticals, Inc. began trading on the Nasdaq Capital Market on January 4 2019 (Nasdaq: SXTC).It is known that the 100-year-old brand “SXT” produces and sells 13 kinds of modern Chinese herbal medicines, more than 60 kinds of refined Chinese herbal medicines and more than 500 types of regular Chinese herbal medicines. The funds raised from IPO are mainly used to expand production facilities, recruit new staff, develop new drugs and for general business operation.
It is reported that China SXT Pharmaceuticals, Inc. will also set up a R&D and production base for “homology of medicine and food” and health food in both the north and south at the same time, and promote an general health industry system. The company aims to maintain continuous lead in the research, development and market of the innovative products of new modern Chinese herbal medicines in China, strives to be the leading enterprise in the production and sales of the modern Chinese herbal medicine products, and build a large and medium-scaled traditional Chinese medicine preparations manufacturer in the future.
- White Paper on Bone and Joint Health of Chinese Consumers 2020
- Yili Dairy launched high-protein yogurt, focusing on sport people
- Sinopharm Xingsha launched the Japan's Champion probiotics
- China has introduced its first policy to support the industrial hemp industry
- Beyond Meat became the first overseas Artificial Meat company to set up a factory in China
- Nongfu Spring's market value exceeded HK $370 billion on its first day
- German infant nutrition brand Amykon launched two probiotics in China
- The revenue of Besunyoung in the first half year is about 610 million yuan
- Jellly candy and powder included in the health food filing dosage form in China
- H&H Group net profit increased by 9% for the first half of year
